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Abstract
Axonal damage and demyelination are major determinants of disability in patients with peripheral demyelinating
neuropathies. The neurotrophin family of growth factors are essential for the normal development and myelination
of the peripheral nervous system (PNS), and as such are potential therapeutic candidates for ameliorating axonal
and myelin damage. In particular, BDNF promotes peripheral nerve myelination via p75 neurotrophin receptor
(p75NTR) receptors. Here, we investigated the therapeutic efficacy of a small structural mimetic of the region of
BDNF that binds to p75NTR (cyclo-DPAKKR) in experimental autoimmune neuritis (EAN), an established animal
model of peripheral demyelinating neuropathy. Examination of rodents induced with EAN revealed that p75NTR is
abundantly expressed in affected peripheral nerves. We found that systemic administration of cyclo-DPAKKR
ameliorates EAN disease severity and accelerates recovery. Animals treated with cyclo-DPAKKR displayed
significantly better motor performance compared to control animals. Histological assessment revealed that
cyclo-DPAKKR administration limits the extent of inflammatory demyelination and axonal damage, and protects
against the disruption of nodal architecture in affected peripheral nerves. In contrast, a structural control peptide
of cyclo-DPAKKR exerted no influence. Moreover, all the beneficial effects of cyclo-DPAKKR in EAN are abrogated
in p75NTR heterozygous mice, strongly suggesting a p75NTR-dependent effect. Taken together, our data demon-
strate that cyclo-DPAKKR ameliorates functional and pathological defects of EAN in a p75NTR-dependant manner,
Significance Statement
This study demonstrates that a BDNF-based peptide mimetic ameliorates the clinical and functional deficits
in experimental autoimmune neuritis (EAN), an animal model of peripheral demyelinating neuropathy.
Concordant with these findings, treatment significantly reduced immune cell infiltration, the extent of
peripheral demyelination and axonal pathology. Genetic analyses identified these effects were mediated
through p75 neurotrophin receptor (p75NTR). This study identifies a novel avenue for myelin and axonal
protection in peripheral demyelinating neuropathy through targeting p75NTR; however, additional studies are
required to identify the precise cellular mechanism underlying these effects. The strong protective effect that
the mimetic exerts on axonal damage paves the way for studying its application in other peripheral
neuropathies in the future.
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suggesting that p75NTR is a therapeutic target to consider for future treatment of peripheral demyelinating
diseases and targeting of p75NTR is a strategy worthy of further investigation.
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Introduction
Demyelination and axonal degeneration are pathologic
hallmarks of injured peripheral nerve in acquired demyeli-
nating peripheral neuropathies (Hughes et al., 2007).
However, current therapies for these diseases are anti-
inflammatory and do not prevent neurologic symptoms
underpinned by persistent demyelination and secondary
axonal degeneration (Hughes et al., 2007), demonstrating
a need for novel neuroprotective therapies that can be
administered as adjuncts to existing immunomodulatory
therapies for the treatment of these diseases.
The neurotrophins are a family of soluble growth factors
essential for peripheral nervous system (PNS) develop-
ment and myelination (Chan et al., 2001; Cosgaya et al.,
2002; Xiao et al., 2009a). They comprise nerve growth
factor (NGF), BDNF, neurotrophin (NT)-3, and NT-4/5.
Their biological effects are mediated via two distinct
classes of receptors: the tropomyosin-related kinase (Trk)
receptors and the p75 neurotrophin receptor (p75NTR;
Kaplan and Miller, 2000). Different neurotrophins exert
distinct influences on peripheral myelination depending
on the cognate receptor expressed by peripheral neurons
(Xiao et al., 2009a). We and others have demonstrated
that BDNF promotes myelination via acting on p75NTR
(Cosgaya et al., 2002; Xiao et al., 2009b), whereas it
inhibits myelination via activating TrkB (Xiao et al., 2009b).
Moreover, analyses of mutant mice indicate that p75NTR is
required for the survival of a subset of peripheral neurons
(Lee et al., 1992). In this context, selective targeting of
p75NTR could be an approach that, in principle, exerts a
beneficial effect on myelin repair and protection against
axonal damage after peripheral nerve injury.
This has led us to develop the cyclic pentapeptide
cyclo-[DPro-Ala-Lys-Lys-Arg] (cyclo-DPAKKR), a struc-
tural mimetic of BDNF (Fletcher et al., 2008). Cyclo-
DPAKKR is presented in a highly conformationally
constrained cyclic template that contains the positively
charged ‘Lys-Lys-Arg’ tri-peptide motif required for BDNF
to bind to p75NTR (Rydén et al., 1995). Importantly, cyclo-
DPAKKR contains no sequence similarity to the loop 2
region of BDNF that binds TrkB and does not cause TrkB
autophosphorylation (Fletcher et al., 2008). Equally, it
contains no sequence similarity to the N-terminal portion
of pro-BDNF that binds the sortilin-p75NTR receptor com-
plex and does not induce the death of sensory neurons or
Schwann cells in culture (Fletcher et al., 2008). Cyclo-
DPAKKR displays drug-like properties, in that it is of low
molecular weight (relative molecular mass of 580), meta-
bolically stable in rodent plasma in vitro and readily
crosses cell membranes (Fletcher et al., 2008; Fletcher
and Hughes, 2009). Collectively, these properties of
cyclo-DPAKKR render it a unique pharmacological tool to
investigate the selective influence of BDNF on p75NTR,
without the concomitant activation of TrkB or the sortilin-
p75NTR proneurotrophin receptor complex. Indeed, we
have previously shown that cyclo-DPAKKR promotes the
survival of peripheral neurons in vitro (Fletcher et al., 2008)
and peripheral nerve myelination in vitro and in vivo, an
effect dependent on the expression of p75NTR (Xiao et al.,
2013).
In this study, we investigated the therapeutic potential
of cyclo-DPAKKR in experimental autoimmune neuritis
(EAN), a well-established model of demyelinating periph-
eral neuropathy. The disease course mirrors many of the
morphologic and electrophysiological aspects of acute
and chronic demyelinating peripheral neuropathy, given
that on the one hand there is acute remission but that
on the other hand there is incomplete recovery (Mäurer
and Gold, 2002; Hughes and Cornblath, 2005; Yuki and
Hartung, 2012). We found that p75NTR is abundantly
expressed in affected peripheral nerves in rodent EAN.
Systemic administration of cyclo-DPAKKR ameliorates
EAN disease course and motor deficits, and reduces
the extent of demyelination and axonal damage, in a
p75NTR-dependent manner. In contrast, a structural
control peptide of cyclo-DPAKKR exerted no influence.
Our data demonstrate that cyclo-DPAKKR exerts
p75NTR-dependent neuroprotective effects in EAN, sug-
gesting that targeting of p75NTR is a strategy worthy of




EAN disease was induced in Lewis rats (10–12 weeks
old, female) bred and maintained at the Liverpool Hospital
Animal Facility, New South Wales, and in C57B6 wild-type
(WT, /) and NGFR/C57B6 (p75NTR heterozygous, HET,
/) mice housed at the Animal Facility of Florey Institute
of Neuroscience and Mental Health Research, the Univer-
sity of Melbourne. The p75NTR HET mice were obtained
from a colony previously shown to be 95% congenic to
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the inbred C57B6 strain (Syroid et al., 2000), and subse-
quently back-crossed a further 12 generations. All animal
procedures were approved by Animal Experimentation
Ethics Committees at the University of New South Wales
and University of Melbourne.
Peptide syntheses and reagents
The conformationally-constrained cyclised active pep-
tide cyclo-DPAKKR (DPro-Ala-Lys-Lys-Arg) and control
peptide (Ala-DPro-Lys-Lys-Arg, cyclo-ADPKKR) were syn-
thesised, purified and characterised as previously de-
scribed (Fletcher et al., 2008; Xiao et al., 2013). All
chemicals were obtained from Sigma-Aldrich unless oth-
erwise indicated.
EAN induction in rats
Adult Lewis rats were induced with EAN disease by
inoculation with a peripheral myelin antigen using pub-
lished methods (Hodgkinson et al., 1994; Tran et al., 2010,
2012). Briefly, 10- to 12-week-old female rats were immu-
nized in the footpad with 200 l of emulsion containing
4mg bovine peripheral nerve myelin and 1.5 mg of com-
plete Freund’s adjuvant prepared by emulsifying heat
killed Mycobacterium tuberculosis (strain H37RA; Difco) in
100 l saline and 100 l incomplete Freund’s adjuvant
(Difco). Animals develop a severe disease initially consist-
ing of paraplegia and eventually quadriparesis. Animals
were monitored daily for weight loss, and clinical disease
was scored as 0 for normal, 1 for limp tail, 2 for hind leg
weakness, 3 for paraplegia, and 4 for quadriplegia.
EAN induction in mice
Adult C57/B6 mice were induced with EAN disease as
previously described (Gonsalvez et al., 2017). Briefly, six-
to eight-week-old male mice (WT and p75 HET) were
immunized twice (day 0 and day 8 after induction) by
subcutaneous injection of myelin basic protein zero (P0)
peptide 180–199 (P0180–199, sequence S-S-K-R-G-R-Q-
T-P-V-L-Y-A-M-L-D-H-S-R-S), and 0.5 mg Mycobacte-
rium tuberculosis (strain H 37 Ra; Difco 231141)
emulsified in 25 l saline and 25 l of complete Freund’s
adjuvant (Difco 263910 comprising; 3.75 l of mannide
monoolate  21.25 l of paraffin oil and 12.5 g of
desiccated killed and dried Myobacterium butyrcum).
Mice received pertussis toxin (Ptx, Sigma) on day 1 (400
ng/mouse), and days 1 and 3 (300 ng/mouse) by intra-
peritoneal injection. All Ptx and inoculation injections were
conducted on mice anesthetized by aerosol isoflurane 2%
in normal air. Animals were monitored daily for weight
loss, and clinical disease was scored as: 0 for normal, 1
for less lively, 2 for mild tail and hindlimb paresis, 3 for
mild ataxia and limb paresis, 4 for severe ataxia and limb
paresis and 5 for limb paralysis.
Cyclo-DPAKKR treatment
EAN animals were intraperitoneally administrated with
cyclo-DPAKKR (0.1–10 mg/kg/d) or vehicle control (PBS)
daily after the day of disease induction (day 0). The doses
of cyclo-DPAKKR were chosen based on its potency in
promoting peripheral nerve myelination in vivo (Xiao et al.,
2013). Rats were killed at day 17, the peak of clinical
disease and when demyelination is maximal, or at day 24
when animals exhibit partial recovery (Tran et al., 2010,
2012). Cauda equina and sciatic nerves were dissected
and prepared for Western blot, immunohistochemical,
histologic, or electron microscopy (EM) analyses as de-
scribed previously (Tran et al., 2002; Xiao et al., 2013). Six
to seven rats per treatment group per time point were
assessed. In some experiments, cyclo-DPAKKR (10 mg/
kg/d), the control peptide (cyclo-ADPKKR, 10 mg/kg/d) or
a vehicle (PBS) control was intraperitoneally administered
to mice (p75NTR HET and WT littermate controls) via mini
osmotic pump (ALZET, CA pump#: 2006). Mice sciatic
nerves were collected at day 23 (disease peak in murine
EAN) and six mice per genotype per treatment group were
assessed.
Quantitative PCR (qPCR)
Total RNA was extracted from cauda equina and sciatic
nerves of healthy control rats and rats subjected to EAN at
day 17 using the QIAGEN RNEAsy kit. Extracted RNA was
reverse transcribed into cDNA, using Taqman Reverse
Transcription reagents (Applied Biosystems). qPCRs were
performed on an Applied Biosystem ABI7700 sequence
detection system and analyzed using the comparative Ct
method. Sequences of primers used were as follows: rat
18S, forward 5’-GCTGGAATTACCGCGGCT-3’, reverse
5’-CGGCTACCACATCCAAGGAA-3’; p75NTR, forward 5’-
AAGGGGCGGGGCATTGTGGTA-3’, reverse 5’-GTTG-
GGTAGGGGCCTGGAAGTGGT-3’. Data are relative to
18S then normalized against the healthy control.
Western blot analysis
To assess myelin protein expression, total protein ly-
sates were prepared from cauda equina and sciatic
nerves from EAN rats, separated by SDS-PAGE and
transferred to PVDF membrane. Membranes were probed
with an antibody against myelin basic protein (MBP;
AB980, Millipore Bioscience Research Reagents), a my-
elin marker, and actin as a loading control. Each blot
shown in the figure is a representative of at least three
independent experiments. Quantification of the Western
blot bands was achieved by scanning the blots using a
FujiFilm LAS-3000 (FujiFilm). The optical density value for
each band was determined using NIH ImageJ, corrected
to a loading control, and then normalized against the
vehicle control conditions.
Animal immunohistochemistry
EAN animals (rats and mice) were perfused transcardi-
ally with 4% PFA, cauda equina and/or sciatic nerves
isolated, frozen, and 10 m cryosections separated by at
least 80 m collected. The cauda equina or sciatic nerve
sections were immunostained with the myelin marker
MBP (AB980, Millipore Bioscience Research Reagents),
amyloid precursor protein (APP; S12700, Invitrogen), pan
voltage-gated Sodium channel (pan-Nav, S8809, Sigma),
contactin-associated protein 1 (Caspr, a generous gift
from Professor Elior Peles, Weizmann Institute of Science,
Israel; Gordon et al., 2014), III-tubulin (G7121, Promega),
IBa1 (WAKO, 019-19741), or p75NTR (G323A, Promega),
followed by the appropriate fluorophore-conjugated sec-
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ondary antibodies (Invitrogen). The sections were then
washed in PBS, and mounted in DAKO mounting medium
with DAPI. Six sections per animal from a minimum of
three animals per group were analyzed, and images cap-
tured by confocal microscopy. The proportion of labeled
cells per section was calculated for each animal, and
averaged across groups.
Transmission EM
Rats were perfused with 4% PFA, cauda equina dis-
sected, postfixed overnight at 4°C in Karnoversusky’s
fixative, and subsequently processed for resin embed-
ding, as previously described (Xiao et al., 2011, 2013).
Semi-thin sections (0.5 m) were cut and stained with
toluidine blue and bright field image taken at 100 mag-
nification. Representative samples were then chosen, and
ultrathin sections (90 nm) were cut. EM images were
captured using a Siemens Stereoskop Transmission Elec-
tron Microscope (Siemens) at 3000 magnification. For
quantification, three to four animals per treatment group
were used, and minimum six images per animal were
taken randomly and analyzed covering the majority of the
nerve sections.
Spectral reflectance confocal microscopy imaging
Spectral reflectance confocal microscopy (SCoRe) im-
aging was performed on sciatic nerve sections to assess
the extent of myelin damage in EAN mice using published
methods (Schain et al., 2014). Briefly, mice were perfused
with 4% PFA, sciatic nerves dissected (2 mm proximal to
the bifurcation of the common peroneal and tibial divi-
sion), frozen and cryosectioned at 12 m. Longitudinal
sections of sciatic nerves were imaged via a Zeiss 780
Meta confocal microscope with a water immersion objec-
tive (Zeiss W Plan-Apochromat 20/1.0 NA DIC M27
70mm) using 458, 561, and 633-nm laser wavelength
through the Tunable Lazer In Tune 488–640 filter/splitter
wheel and a 20/80 partially reflective mirror. The reflected
light was collected using three photodetectors set to
collect light through narrow bands defined by prism and
mirror sliders, centered around the laser wavelengths 488,
561, and 633 nm. The channels from each photodetector
were then additively combined as a one color composite.
All images were acquired using the same settings, ana-
lyzed by an operator blinded to conditions using NIH Fiji
(ImageJ) software with the threshold function and a min-
imum cutoff for positive pixels set at 50. The percentage
area of positive signal was computed for each image. For
quantification, a minimum three tile scans (three images
per tile, using a 20/1.0NA objective at a z-depth 4 m
from the tissue surface) per treatment group were used
and statistically analyzed.
Functional running task assessment
To assess functional outcomes following cyclo-
DPAKKR treatment in EAN, animals were videoed on a
transparent treadmill using the DigiGait 8 program system
(eMouse Specifics) as previously described (Gonsalvez
et al., 2017). A simple running task was designed, in which
mice were set to complete a 36-s run at a treadmill speed
of 15 cm/s. Mice that could not maintain running for the
36-s interval were deemed to fail, as described previously
(Gonsalvez et al., 2017). During the running task, video
was captured and the running time before failure was
analyzed using the DigiGait 8 program. Mice were tested
with the running task every 3 d. It typically took 15- to 20-s
running time for mice to successfully complete 10 contin-
uous uninterrupted steps as previously described (Gon-
salvez et al., 2017).
Statistical analysis
All data are presented as mean  SEM, or mean  95%
confidence interval. Differences between pairs of groups
for clinical scores were tested by Mann–Whitney U test.
Repeated measures two-way ANOVA testing was used to
determine the interaction between groups and time, and
genotypes, in all cases significance was set at p  0.05.
All statistical testing was performed using GraphPad
Prism 6 software.
Results
Expression of p75NTR is increased in EAN nerves
to investigate whether targeting p75NTR is a potential
therapeutic strategy for treating peripheral demyelinating
diseases, we sought to first determine the level of p75NTR
expression in injured peripheral nerves of rats subjected
to EAN at disease peak (day 17) and age-matched health
control (non EAN) rats (Fig. 1). We found a low level of
p75NTR expression detected in the cauda equina of
healthy adult rats (Fig. 1A), whereas abundant p75NTR
expression was observed in the cauda equina of rats
subjected to EAN (Fig. 1B). Further, qPCR analysis re-
vealed a significant increase in p75NTR mRNA expression
in the cauda equina and sciatic nerves of rats subjected to
EAN compared with age-matched healthy control rats
(Fig. 1C, n  3–4/group, p  0.05). Thus, our results
demonstrate that p75NTR expression (both mRNA and
protein) is increased in the effected peripheral nerves of
rats subjected to EAN.
Cyclo-DPAKKR ameliorates EAN disease severity in
a dose-dependent manner
To investigate whether targeting p75NTR via cyclo-
DPAKKR exerts any beneficial influence on EAN, rats
received daily intraperitoneal administration of cyclo-
DPAKKR over four orders of magnitude (0.1, 1, 3, and 10
mg/kg) or vehicle control (saline) from day 1 (1 day after
disease induction) for 17 d. Our data show that cyclo-
DPAKKR administration significantly ameliorated EAN dis-
ease severity at the two higher doses (3 mg/kg: p  0.01
and 10 mg/kg: p  0.001), but not the two lower doses
(0.1 mg/kg: p  0.78 and 1 mg/kg: p  0.15), compared
with the vehicle control (Fig. 2A). In addition, animals
treated with cyclo-DPAKKR at 10 mg/kg, but not 3 mg/kg,
displayed a significant delay (3 d) in the onset of EAN
disease compared with the vehicle control group (Fig. 2A,
p  0.05).
EAN disease in rats is a monophasic disease that ex-
hibits a stereotypical progression. Following the disease
peak at approximately day 17, animals usually undergo a
limited degree of spontaneous recovery with a reduction
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in disease severity (Tran et al., 2010). We next sought to
determine if the administration of cyclo-DPAKKR beyond
the peak of disease (day 17) ameliorates disease progres-
sion and promotes recovery. To do this, EAN was induced
in a separate cohort of rats that received daily intraperi-
toneal administration of cyclo-DPAKKR (10 mg/kg) or ve-
hicle from day 1 for 24 d (Fig. 2B). Concordant with the
data above (Fig. 2A), cyclo-DPAKKR administration signif-
icantly delayed the disease onset (3 d) compared with
vehicle-treated control rats (Fig. 2B, p  0.05). Delivery
of cyclo-DPAKKR beyond the peak of disease continued
to ameliorate EAN disease severity compared with the
vehicle-treated control group, with animals treated with
cyclo-DPAKKR displaying a more rapid reduction in dis-
ease scores during the recovery phase compared with
vehicle-treated control animals (Fig. 2B, n  6–7 mice/
group, p  0.01), suggesting that treatment with cyclo-
DPAKKR beyond disease peak accelerates recovery in
EAN.
Cyclo-DPAKKR abrogates myelin damage in EAN
Demyelination and axonal degeneration are key patho-
logic features of rodents with EAN and patients with
demyelinating peripheral neuropathy, and ultimately influ-
ences disease prognosis (Nagappan and Lu, 2005). Hav-
ing shown that cyclo-DPAKKR ameliorates the clinical
deficits in rat EAN (Fig. 2), we next sought to determine
the neuropathological basis for its beneficial effects. We
first measured expression of the integral myelin protein
MBP in injured peripheral nerves via Western blot and
immunohistochemical analyses (Fig. 3A–D). Both sciatic
nerves and cauda equina were dissected at days 17 and
24, followed by total protein extraction and probing with
an antibody directed against MBP. We found significantly
more MBP expression in both peripheral nerves of EAN
rats treated with cyclo-DPAKKR at both time points com-
pared with vehicle-treated controls (Fig. 3A,B, p  0.05).
This result was confirmed by assessing MBP protein
expression on cauda equina sections using immunohis-
tochemistry (Fig. 3C,D, p  0.05). Collectively, these
data suggest that cyclo-DPAKKR administration protects
against the loss of myelin protein expression in injured
peripheral nerves of EAN animals in vivo.
To further determine the extent of myelin pathology in
these animals, we undertook an ultrastructural analysis of
myelinated axons via histology and EM (Fig. 3E–H). We
first assessed the percentage of myelinated axons at two
time points (days 17 and 24). Our data revealed signifi-
cantly more myelinated axons in the cauda equina of rats
subjected to EAN and treated with cyclo-DPAKKR com-
pared with vehicle-treated controls at both time points
(Fig. 3E, quantitated in F, p  0.05). We also examined
the density of axons, calculating the data as a percentage
relative to healthy control (no EAN) rats (Fig. 3E, quanti-
tated in G). We also quantitated axonal numbers and
found that the number of axons in vehicle-treated animals
was significantly reduced to 30–40% of the healthy con-
trol, whereas cyclo-DPAKKR administration protected
against axonal loss at disease peak and during recovery
(60% of healthy control; Fig. 3G, n  3–4/group/time
point, p  0.05), supporting out prior finding that cyclo-
DPAKKR treatment reduces the extent of demyelination at
the peak of disease and during the recovery phase in EAN
(Fig. 3F).
To further determine if cyclo-DPAKKR exerts a protec-
tive influence on myelin integrity in EAN, we assessed
myelin ultrastructure via EM analysis (Fig. 3H). Concor-
dant with the bright field images (Fig. 3E), we found
substantially more myelinated axons in the cauda equina
of cyclo-DPAKKR-treated groups compared with vehicle
controls at both time points (Fig. 3H), further suggesting
that cyclo-DPAKKR limits the extent of demyelination. It is
well established that in patients with demyelinating
peripheral neuropathy and animals with EAN, injured pe-
ripheral nerves commonly display patterns of macro-
phage-mediated demyelination such as phagocytosis of
compact myelin lamellae following the displacement of
the normal-appearing Schwann cell outer mesaxon from
the compact myelin membrane (Carenini et al., 2001;
Pollard and Armati, 2011). To determine if cyclo-DPAKKR
reduced the extent of inflammatory demyelination, we
Figure 1. P75NTR expression is increased in injured nerves of rat EAN. A, B, Representative immunohistochemical images of p75NTR
and neurofilament (NfM) staining on transverse sections of cauda equine from healthy adult (control, A) and EAN rats (B).
Immunoreactivity for p75NTR protein is substantially greater in cauda equina sections of EAN rats than healthy controls. Scale bar, 20
m. C, p75NTR mRNA expression in cauda equina and sciatic nerves of health and EAN rats via qPCR analysis. P75NTR mRAN is
significantly upregulated in both cauda equina and sciatic nerves of EAN rats than healthy controls (data: mean  SEM, relative to
18S then normalized against the healthy control, two-way repeated measures ANOVA p  0.01, n  3–4/group).
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assessed EM images at a higher-magnification. We found
that cyclo-DPAKKR treatment markedly limited the extent
of macrophage-mediated demyelination in EAN com-
pared with vehicle-treated animals (Fig. 3H). In the cauda
equina of vehicle-treated rats, we readily observed com-
pact myelin being stripped from an axon by a macro-
phage filled with myelin debris (Fig. 3H, panels a,a’,
macrophage shown in panel a’) and the normal appearing
myelin sheath penetrated with macrophages (Fig. 3H,
panels b,b’). However, these patterns of macrophage-
mediated demyelination were rarely observed in the
cauda equina of cyclo-DPAKKR-treated animals (Fig. 3H),
suggesting a limited extent of inflammatory demyelina-
tion. The activation, proliferation and recruitment of
phagocytic macrophages are a key innate cellular re-
sponse that contributes to inflammatory demyelination in
EAN (Xia et al., 2010). Having shown limited macrophage-
mediated demyelination following cyclo-DPAKKR treat-
ment in EAN (Fig. 3H), we next investigated macrophage
infiltration in the injured peripheral nerves of these animals
and found that cyclo-DPAKKR treatment significantly re-
duced the number of infiltrating IBa1 macrophages in
cauda equina sections at disease peak (day 17) compared
with vehicle-treatment (Fig. 3I, quantitated in J, n  3–4/
group, p  0.05), indicating that cyclo-DPAKKR admin-
istration influences the extent of macrophage infiltration
into affected peripheral nerves in EAN. Together, our data
demonstrate that cyclo-DPAKKR exerts a protective effect
on myelinated peripheral nerves subjected to EAN, in
particular reducing the extent of demyelination.
Figure 2. Cyclo-DPAKKR ameliorates EAN in a dose-dependent manner. Time course of disease severity in rats subjected to EAN
following daily administration of either vehicle control or Cyclo-DPAKKR from day 1 (data: mean  SEM, n  6–7/group,
Mann–Whitney U test). A, Cyclo-DPAKKR reduced disease severity in rat EAN in a dose-dependent manner (3 mg/kg group: p 
0.01, 10 mg/kg group: p  0.001). B, EAN rats treated with cyclo-DPAKKR beyond the disease peak (day 17) exhibited a significantly
faster recovery compared with vehicle controls (p  0.001).
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Cyclo-DPAKKR reduces the extent of axonal damage
in EAN
Increasing evidence suggest that myelin loss ultimately
leads to the degeneration of exposed axons, which cor-
relates with the progression of disability in human
autoimmune-mediated peripheral demyelinating neurop-
athies and rodent EAN (Bechtold et al., 2005; Pollard and
Armati, 2011; Kieseier et al., 2012). Having shown that
cyclo-DPAKKR limits the extent of demyelination in EAN,
we next sought to determine if it also limits axonal degen-
eration. To do this, we first assessed the accumulation of
axonal spheroids containing APP, a robust indicator of
acute axonal damage to axonal structure (Trapp et al.,
1998) in the longitudinal sections of cauda equina of
animals subjected to EAN at peak (day 17) and recovery
(day 24; Fig. 4A,B). We found that APP axonal spheroids
( axonal spheroids of 3–5 m in diameter) were clearly
visible in vehicle-treated animals (Fig.4 A, approximately
5 per longitudinal section). Animals treated with cyclo-
DPAKKR displayed a significant reduction in the accumu-
lation of APP axonal spheroids compared with vehicle-
treated control animals at both time points (Fig. 4A,
quantitated in B, n  3–4/group/time point, p  0.05),
suggesting that cyclo-DPAKKR exerts a neuroprotective
effect on acute nerve damage in EAN.
It has been shown that disruptions of the nodal and
paranodal architecture represent the site of axonal pathol-
ogy in rodent EAN (Pollard and Armati, 2011) and in
patients with chronic inflammatory demyelinating poly-
neuropathy (CIDP; Cifuentes-Diaz et al., 2011; Doppler
et al., 2016). Thus, we investigated the expression of
proteins normally clustered at the node of Ranvier and
paranodes required for fast axonal conduction (Vabnick
and Shrager, 1998). Longitudinal sections of the cauda
equina were immunolabeled for voltage-gated pan-
sodium channels (pan-Nav) and Caspr, proteins normally
localized to the node and paranode, respectively (Arroyo
et al., 1999; Gordon et al., 2014; Fig. 4C), and quantified
nodal and paranodal densities (Fig. 4D,E). In the vehicle-
treated group, we found significantly fewer pan-Nav-
expressing nodes (Fig. 4D, p  0.05) and Caspr-
expressing paranodes (Fig. 4E, p  0.05) compared with
healthy (no EAN) control animals. However, these
changes of nodal architecture in EAN are rescued by the
treatment of cyclo-DPAKKR. We found cyclo-DPAKKR ad-
ministration resulted in significantly more pan-Nav-
expressing nodes (Fig. 4D, p  0.05) and Caspr-
expressing paranodes (Fig. 4E, p  0.05) compared with
vehicle-treated animals at both time points, suggesting a
protective effect on nodal structure. We also observed
that asymmetrical nodes and heminodes (Fig. 4C, ar-
rows), an indicator of structural damage to nodes and
paranodal demyelination in CIDP nerves (Cifuentes-Diaz
et al., 2011), were visible in animals subjected to EAN but
not in healthy control animals (data not shown). Quantifi-
cation of the density of heminodes revealed significantly
fewer heminodes in the nerves of cyclo-DPAKKR-treated
animals compared with vehicle controls (Fig. 4F, p 
0.05), further suggesting that cyclo-DPAKKR protects the
architecture of nodes and paranodes in EAN. Together,
our data demonstrate that cyclo-DPAKKR reduces the
extent of demyelination and protects against axonal dam-
age in EAN.
Cyclo-DPAKKR exerts p75NTR-dependent therapeutic
effects in EAN
The tripeptide ‘KKR’ motif is the region of BDNF that
binds to p75NTR (Rydén et al., 1995). The head to tail
DPro-Ala cyclisation of cyclo-DPAKKR presents the ‘KKR’
motif in the same structural conformation as BDNF
(Fletcher et al., 2008). To determine if the beneficial ef-
fects that cyclo-DPAKKR exert on EAN is p75NTR-
dependent, we synthesized a control cyclised peptide
(cyclo-ADPKKR) containing the same ‘KKR’ p75NTR bind-
ing motif of cyclo-DPAKKR, but in a different conformation
as it is contained by a different linker (Ala-LPro; Fig. 5A).
We have previously shown that this altered conforma-
tional state can abolish the trophic effect that cyclo-
DPAKKR exerts on peripheral neurons in vitro (Fletcher
et al., 2008).
In this study, both cyclo-DPAKKR and the cyclised
control peptide cyclo-ADPKKR were administered to mice
subjected to EAN via daily intraperitoneal administration
from day 1 for 23 d, and disease progression assessed by
daily clinical scoring and DigiGait functional analysis (Fig.
5B,C). Concordant with the rat EAN data (Fig. 2), admin-
istration of cyclo-DPAKKR in murine EAN significantly
ameliorated disease severity and delayed the onset of
Figure 3. Cyclo-DPAKKR limits the extent of myelin and axonal pathology in EAN. Analyses of cauda equina or sciatic nerves isolated
from age-matched healthy control (no EAN) or rats subjected to EAN at day 17 or day 24 after daily treatment with Cyclo-DPAKKR
(10 mg/kg) or vehicle control (data: mean  SEM, n  3–4/group/time point, two-way repeated measures ANOVA p  0.05). A, B,
Western blot (A) and densitometric analyses (B) of Western blot bands from cauda equina and sciatic nerve lysates of EAN rats at day
17. C, D, Immunohistochemistry against the myelin marker MBP (C) and quantitation of MBP intensity (D) in cauda equina sections
from EAN rats. Scale bar, 50 m. E, Representative toluidine blue staining images of cauda equine. Scale bar, 10 m. F, Quantification
of the percentage of myelinated axons in cauda equine. There are significantly more myelinated axons in animals treated with
Cyclo-DPAKKR than vehicle controls. G, Quantification of the axonal density in cauda equina. Axonal density in EAN rats is expressed
as a percentage of axonal density in health control rats. Axonal density in vehicle-treated animals was significantly reduced by almost
60–70% (30–40% of healthy control), whereas Cyclo-DPAKKR administration protected the axonal loss (60% of healthy control).
H, Representative electron micrographs of myelinated axons in cauda equina. Scale bar, 2 m. Panel a’ (a higher magnification image
from panel a) shows macrophage-mediated demyelination, as evident by the last vestige of compact myelin being stripped from an
axon by a macrophage filled with compact myelin debris. Panel b’ (a higher magnification image from panel b) shows the normal
appearing myelin sheath penetrated with macrophages (arrows indicate myelin fragments). I, Representative immunohistochemical
images of IBa1 (a marker for macrophages) in transvers sections of cauda equina of rats subjected to EAN at disease peak (day 17).
Scale bar, 50 m. J, Quantification of IBa1 macrophages from (F) reveals that Cyclo-DPAKKR significantly reduced macrophage
infiltration in injured nerves compared with vehicle controls.
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Figure 4. Cyclo-DPAKKR protected against axonal degeneration in EAN. Analyses of cauda equina isolated from rats subjected to
EAN at day 17 or day 24 after daily treatment with Cyclo-DPAKKR (10 mg/kg) or vehicle control, or age-matched healthy control rats
(no-EAN). A, B, Representative immunohistochemical images of APP (A) and quantitation of APP axonal spheroids (B) in longitudinal
sections of cauda equina isolated from rats subjected to EAN. Administration of Cyclo-DPAKKR resulted in significantly fewer APP
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disease (2 d) compared with the vehicle-treated control
mice (Fig. 5B, n  6 mice/group, p  0.0001). In
contrast, the structural control peptide cyclo-ADPKKR ex-
erted no significant effect compared with vehicle-treated
controls (Fig. 5B, n  6 mice/group, p  0.477). The
finding that cyclo-DPAKKR, but not cyclo-ADPKKR, ame-
liorates EAN disease severity is also supported by the
functional running task assessed by DigiGait analysis. All
EAN mice were subjected to a regular running task as-
sessment every 3 d and the running time before failure
were analyzed (Fig. 5C). We found both the vehicle and
control peptide-treated mice began to display a signifi-
cant drop in their running time from day 9 to 11, whereas
the running time of cyclo-DPAKKR-treated mice did not
show a significant drop until approximately day 20 (Fig.
5C, p  0.05, n  6 mice/group), suggesting an amelio-
rated motor deficit. Moreover, cyclo-DPAKKR-treated
mice displayed a significantly prolonged running time
compared with the vehicle control group from day 9 on-
wards (Fig. 5C, p  0.05, n  6 mice/group), further
suggesting better motor performance. In contrast, the
control peptide exerted no significant influence on running
capacity compared with the vehicle control (Fig. 5C).
Collectively, these results suggest that the conformational
constraint component within cyclo-DPAKKR itself deter-
mines its therapeutic effect by facilitating its interaction
with p75NTR. Our findings that the control peptide cyclo-
ADPKKR failed to influence the disease course and motor
capacity of mice subjected to EAN indicate that the ther-
apeutic effect of cyclo-DPAKKR is not due to an immune-
mediated effect possibly caused by treatment with a
peptide.
We further went to determine if cyclo-DPAKKR exerted
its effects in a p75NTR-dependent manner using p75NTR
HET mice. As p75NTR KO (/) mice display a develop-
mental loss of 	50% sensory neurons in the PNS (Lee
et al., 1992; Murray et al., 1999) potentially confounding
interpretation in this study, p75NTR HET mice were used.
P75NTR HET and WT littermate control mice were induced
with EAN, and either untreated, or treated with cyclo-
DPAKKR or cyclo-ADPKKR (the control peptide) daily from
day 1 for 23 d. Daily clinical scoring revealed no significant
difference between disease progression in the untreated
p75NTR HET and control WT mice (data not shown), sug-
gesting that p75NTR haploinsufficiency does not influence
EAN severity and progression. We found that the clinical
scores of p75NTR HET mice treated with cyclo-DPAKKR
were significantly higher compared with cyclo-DPAKKR-
treated WT mice (Fig. 6A, n  6 mice/genotype/group,
p  0.0001), suggesting that p75NTR haloinsufficiency
attenuates cyclo-DPAKKR’s therapeutic effect. In con-
trast, the control peptide (cyclo-ADPKKR) exerted no sig-
nificant effect on disease course between genotypes (Fig.
6C, n  6 mice/genotype/group). These data further sup-
port the perspective that the conformational constraint
component within cyclo-DPAKKR itself is critical for this
effect, which is consistent with the data shown in Figure
5B. Moreover, there was no significant difference in dis-
ease severity between cyclo-DPAKKR and control peptide
treatment in p75NTR HET (Fig. 6E, n  6 mice/genotype/
group). These clinical scores data are supported by the
functional motor performance assessed by Digi-gait anal-
ysis (Fig. 6B,D,F). We found that WT mice treated with
cyclo-DPAKKR performed significantly better in a running
task compared with cyclo-DPAKKR-treated HET mice, as
evidenced by a significantly prolonged running time (Fig.
6B, n  6 mice/genotype/group, p  0.05). In contrast,
the control peptide (cyclo-ADPAKKR) exerted no signifi-
cant influence on running capacity between genotypes
(Fig. 6D, n  6 mice/genotype/group). In addition, there is
no significant difference in running times between cyclo-
DPAKKR or control peptide-treated p75NTR HET mice (Fig.
6F, n  6 mice/genotype/group). Together, our results
demonstrate that p75NTR haloinsufficiency attenuates
cyclo-DPAKKR’s beneficial effect on ameliorating clinical
and functional deficits induced by EAN, suggesting that
p75NTR expression is necessary for the therapeutic influ-
ence that cyclo-DPAKKR exerts on EAN.
Cyclo-DPAKKR exerts a p75NTR-dependent effect on
neuropathology in EAN
To identify neuropathological evidence of a p75NTR-
dependent therapeutic effect of cyclo-DPAKKR in EAN,
we next assessed the extent of demyelination and axonal
degeneration via histology. It has recently been demon-
strated that myelin has unique physical properties making
it the only structure within neural tissues capable of re-
flecting light (Schain et al., 2014). To take advantage of
the high refractive index of lipid-rich compact myelin, the
SCoRe imaging method has been recently developed to
assess myelinated axons in vivo in both healthy and
pathologic conditions (Schain et al., 2014). Here, we ex-
amined the extent of myelin damage on longitudinal sec-
tions of sciatic nerve from mice subjected to EAN using
SCoRe imaging (Fig. 7A,B). We found that WT mice
treated with cyclo-DPAKKR demonstrate a significantly
higher percentage of reflected signal compared with mice
treated with the control peptide (Fig. 7A, quantitated in B,
p  0.05), indicating a greater percentage of compact
myelin per area assessed. Concordant with the clinical
and functional assessments (Fig. 6), cyclo-DPAKKR ex-
erted no significant influence on SCoRe signal in p75NTR
continued
axonal spheroids compared with vehicle controls (data: mean  SEM, n  3–4/group/time point, two-way repeated measures ANOVA
p  0.01, scale bar, 20 m). C, Representative immunohistochemical images of pan-Nav (red) and Caspr (green) expression in
longitudinal sections of cauda equina of rats subjected to EAN or health controls. Scale bar, 20 m, arrows indicate heminodes. D,
E, Quantitation of the density of pan-Nav-expressing nodes (D) and Caspr-expressing paranodes (E) at nodes of Ranvier in the cauda
equina of rats subjected to EAN or health controls (data: mean  SEM, n  3–4/group/time point, p  0.05). F, Quantitation of the
density of heminodes at nodes of Ranvier from C showing significantly fewer heminodes in cyclo-DPAKKR-treated animals compared
with controls (data: mean  SEM, n  3–4/group/time point, p  0.05).
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Figure 5. Conformational constraint in Cyclo-DPAKKR determines its therapeutic effect on EAN. A, The sequence structure of the
cyclic pentapeptide Cyclo-DPAKKR and its control peptide (cyclo-ADPKKR). Cyclo-DPAKKR is a circular peptide containing a
tripeptide motif (KKR) from BDNF shown to bind to p75NTR. Cyclo-ADPKKR (control peptide) is also a cyclic pentapeptide containing
the same p75NTR-binding motif as Cyclo-DPAKKR, but with altered position of Ala and DPro. The five amino acid residues for both
peptides are indicated. B, Time courses of EAN disease severity following daily intraperitoneal delivery of either vehicle, cyclo-
DPAKKR (10 mg/kg/d) or control peptide (cyclo-ADPKKR, 10 mg/kg/d) in mice after disease induction from day 1. Clinical scores: 0,
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HET mice compared with the control peptide (Fig. 7A,B),
indicating that cyclo-DPAKKR requires the expression of
p75NTR to confer beneficial influence on myelin in EAN.
Widening of the node of Ranvier, an indicator of demy-
elination and axonal damage, is one of the pathologic
features commonly observed in peripheral demyelinating
neuropathy (Griffin et al., 1996). Next we examined if
cyclo-DPAKKR treatment can influence nodal widening in
EAN mice via measuring the distance between the paired
Caspr paranodes in longitudinal sciatic nerve sections
of mice treated with cyclo-DPAKKR or control peptide
(Fig. 7C, quantitated in D). Caspr heminodes were ex-
cluded from this analysis. We found that the node length
is significantly shorter in WT mice treated with cyclo-
DPAKKR compared with those treated with control pep-
tide (Fig. 7D, p  0.05), suggesting that cyclo-DPAKKR-
protects against nodal widening. Moreover, cyclo-DPAKKR
failed to influence nodal length widening in p75NTR HET
mice (Fig. 7C,D). There was no significant difference in the
nodal length between WT and p75NTR HET mice treated
with the control peptide (Fig. 7C,D). Collectively, our data
suggest that cyclo-DPAKKR requires the normal expres-
sion of p75NTR to exert its beneficial influence on nodal
structures and axonal damage in EAN.
We further investigated whether cyclo-DPAKKR exerts
p75NTR-dependent effects on axonal degeneration via as-
sessing the accumulation of APP in mice subjected to
EAN (Fig. 7E,F). APP axonal spheroids were readily
visible along injured peripheral nerves in the rat model of
EAN (Fig. 4A); however, only APP axonal segments, but
not axonal spheroids, were observed in the murine model
of EAN (Fig. 7E), suggesting the extent of overall axonal
degeneration is less severe in the murine EAN model
compared with the rat model. As such we decided to
analyze the percentage of APP immunostaining that
was colocalized with the neuronal marker III-tubulin (a
mask was created using the III-tubulin signal and the
percentage area of positive APP signal was computed;
Fig.7E, quantitated in F). We found that in WT mice,
cyclo-DPAKKR treatment significantly reduced the per-
centage of APP/II-tubulin colocalization compared
with the control peptide group (Fig. 7E, quantitated in F,
n  3 mice/genotype/group, p  0.001), supporting
our data observed in rat EAN (Fig. 4A). Concordant with
clinical, functional and myelin assessments (Figs. 6 and
7A-D), the protective effect that cyclo-DPAKKR exerts
against axonal degeneration is abolished in p75NTR HET
mice, in which cyclo-DPAKKR exerted no significant influ-
ence on the percentage of APP axonal area compared
with the control peptide-treated group (Fig. 7E,F). More-
over, we found that control peptide treatment exerted no
significant effect on the percentage of APP axonal area
between genotypes (Fig. 7E,F). Together, our data pro-
vide strong neuropathological evidence that p75NTR ex-
pression is required for the protective effects that cyclo-
DPAKKR exerts against myelin and axonal pathology in
EAN, indicating that it ameliorates EAN-induced neuropa-
thology in a p75NTR-dependent manner.
Discussion
In this study, we show that a conformationally con-
strained BDNF-based p75NTR peptide ameliorates func-
tional, axonal and myelin pathologies induced by EAN
disease in both rats and mice. Importantly, these benefi-
cial effects are abolished when the genetic dose of the
p75NTR is halved. Together, our data suggest that target-
ing p75NTR is a novel therapeutic strategy that ameliorates
demyelination and axonal degeneration induced by pe-
ripheral demyelinating diseases.
Cyclo-DPAKKR limits the extent of functional deficits
and neuropathology in EAN
The altered expression of the neurotrophins and p75NTR
in experimental models of peripheral nerve injury and in a
range of human peripheral neuropathies (Yamamoto
et al., 1998) has resulted in speculation that the neurotro-
phins could be involved in the pathogenesis and repair of
these diseases (Pittenger and Vinik, 2003; Anand, 2004;
Zhou and Notterpek, 2016). Two recent studies have
investigated the potential of using BDNF as a therapeutic
strategy to treat peripheral demyelinating neuropathy.
Treatment with recombinant BDNF in rat EAN failed to
improve neurologic and motor deficits (Felts et al., 2002).
Further, transplantation of BDNF-treated Schwann cells
also failed to ameliorate rat EAN (Hou et al., 2013). Con-
sistent with these findings, we found that administration
of recombinant BDNF failed to promote the myelination of
developing peripheral nerves in vivo (Xiao et al., 2013),
although it is able to enhance Schwann cell myelination in
vitro (Xiao et al., 2009b). These studies together demon-
strate that BDNF itself is not an optimal therapeutic can-
didate for treating demyelinating diseases. While the
precise reason why BDNF exerts no beneficial effect on
myelination during development and rodents subjected to
EAN in vivo remains unclear, it is important to be cogni-
sant of the poor drug-like properties of BDNF and the
complexity of BDNF signaling (Chao, 2003), in particular in
the context of myelination (Xiao et al., 2009b). In this case,
we have identified that targeting of p75NTR, a positive
regulator of both peripheral neuron survival and myelina-
tion (Lee et al., 1992; Cosgaya et al., 2002; Xiao et al.,
2009b), could be a new approach that can protect the
PNS after injury.
continued
normal; 1, less lively; 2, mild tail and hindlimb paresis; 3, mild ataxia and limb paresis; 4, severe ataxia and limb paresis; and 5, limb
paralysis. Cyclo-DPAKKR, but not control peptide, significantly delayed the onset of disease and reduced EAN severity compared with
control peptide (data: mean  SEM, two-way repeated measures ANOVA p  0.0001, n  6 mice/group). C, Running time before
failure in a DidgiGait treadmill running task at moderate speed (15 cm s1). Cyclo-DPAKKR significantly prolonged running capacity
in EAN compared with control peptide or vehicle control (data: mean  SEM, two-way repeated measures ANOVA p  0.05, n 
6 mice/group).
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Figure 6. Cyclo-DPAKKR ameliorates EAN in a p75NTR-dependent manner. A, C, E, Time courses of EAN disease severity following
daily intraperitoneal delivery of either cyclo-DPAKKR (10 mg/kg/d) or control peptide (cyclo-ADPKKR, 10 mg/kg/d) in p75NTR HET or
WT littermate control mice after disease induction from day 1 (n  5–6 mice/genotype/group). B, D, F, Running times before failure
in a DidgiGait treadmill running task (speed, 15 cm s1). A, B, Cyclo-DPAKKR significantly reduced mean clinical scores (A) and
improved running capacity (B) in WT mice compared with HET mice (data: mean  SEM, two-way ANOVA with repeated measures,
p  0.0001 and p  0.05). C, D, No significant difference in clinical scores (C) and running times (D) between WT and HET mice
treated with the control peptide (cyclo-ADPKKR). E, F, No significant difference in clinical scores (E) and running times (F) between
for HET mice treated wither with cyclo-DPAKKR or control peptide.
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We have previously identified that cyclo-DPAKKR pro-
motes the survival and myelination of peripheral neurons
(Fletcher et al., 2008; Fletcher and Hughes, 2009; Xiao
et al., 2013). In this study, we have demonstrated that
cyclo-DPAKKR administration significantly ameliorated
EAN disease severity and accelerated recovery compared
with controls. Cyclo-DPAKKR-treated animals displayed
significantly better motor performance compared with
both vehicle and control peptide-treated groups. More-
over, these functional benefits of cyclo-DPAKKR are
strongly supported by the limited extent of neuropathol-
ogy, as evident by reduced demyelination and axonal
damage as well as immune cell infiltration in injured
nerves compared with control groups. Importantly, anal-
ysis of the node of Ranvier revealed that the loss of
Nav-expressing domains, disruption of paranodal struc-
tures and widening of the nodal length, as are also ob-
served in human peripheral demyelinating neuropathy
(Griffin et al., 1996; Pollard and Armati, 2011), were atten-
uated in cyclo-DPAKKR-treated animals. This finding is
particularly interesting as it suggests that cyclo-DPAKKR
treatment exerts protective effects on the axo-glial junc-
tion and reduces the extent of paranodal demyelination in
EAN. There is an emerging consensus that the progres-
sion of disability in human peripheral demyelinating neu-
ropathy and rodent EAN correlates with the accumulation
of axonal damage, which in turn is influenced by the
extent of demyelination (Bechtold et al., 2005; Pollard and
Armati, 2011; Kieseier et al., 2012). Together, our data
indicate that cyclo-DPAKKR treatment either reduces the
extent of demyelination, or promotes more complete re-
myelination, with the net effect of reducing axonal dam-
age, providing strong anatomic evidence that supports
the improved functional outcomes in EAN.
Cyclo-DPAKKR’s effects are p75NTR dependent
Both BDNF and cyclo-DPAKKR have previously been
shown to promote peripheral nerve myelination via
p75NTR (Xiao et al., 2009b, 2013). In this study, our data
consistently demonstrate that p75NTR expression is re-
quired for the beneficial influence that cyclo-DPAKKR ex-
erts on EAN disease severity, motor function, myelin and
axonal pathology. It is interesting that cyclo-DPAKKR
failed to ameliorate EAN induced disease in p75NTR HET
mice that still express p75NTR, but at a reduced level,
suggesting that the beneficial effect of cyclo-DPAKKR
may require a threshold level of p75NTR expression, which
ultimately leads to optimal downstream p75NTR signaling.
This speculation can also partially explain our finding that
cyclo-DPAKKR exerts a dose-dependent effect on EAN.
Nevertheless, our data strongly suggest that cyclo-
DPAKKR exerts a therapeutic effect on EAN which is
dependent on p75NTR expression. This is further sup-
ported by the finding that the cyclised control peptide
(cyclo-ADPKKR), that contains the same ‘KKR’ p75NTR
binding motif of cyclo-DPAKKR, but in an altered confor-
mational state, exerted no influence on EAN. This result
indicates that the beneficial effects that cyclo-DPAKKR
exert on EAN are crucially dependent on the proper con-
formation of the ‘KKR’ p75NTR binding motif. The lack of
effect of cyclo-ADPKKR compared with cyclo-DPAKKR
reflects our previous observations when examining neu-
ronal survival in vitro (Fletcher et al., 2008). We have
previously shown that cyclo-DPAKKR adopts a single
highly constrained conformation in solution (Fletcher
et al., 2008). It is therefore not surprising that even a
seemingly modest change in the linker could lead to a
dramatic change in conformational preference, sufficient
to alter ligand-receptor interactions and subsequent
downstream signaling. Ultimately, a greater understand-
ing of the molecular interaction, specificity, binding affinity
and stoichiometry between cyclo-DPAKKR and p75NTR is
required to definitively identify the molecular basis of the
differential effects of cyclo-DPAKKR and cyclo-ADPKKR
on EAN.
At a cellular level, it remains interesting to determine the
cell type(s) that cyclo-DPAKKR targets to ameliorate EAN.
It is well established that p75NTR is expressed in neurons
and Schwann cells, and it promotes the viability of sub-
sets of peripheral neurons (Lee et al., 1992; Murray et al.,
1999) and influences Schwann cell myelination (Cosgaya
et al., 2002; Chan et al., 2006) during development. We
and others have shown that p75NTR KO mice display a
loss of 	50% sensory neurons compared with WT mice
(Lee et al., 1992; Murray et al., 1999). It has, however,
been uncertain as to whether this effect is mediated via
loss of p75NTR signaling in isolation, or whether it is due to
the loss of signaling through “high-affinity” neurotrophin
receptor complexes (i.e. p75NTR in combination with the
Trk receptors). Interestingly, we have previously demon-
strated that cyclo-DPAKKR promotes the survival of puri-
fied embryonic chick sensory neurons in culture (Fletcher
et al., 2008), strongly suggesting that selective p75NTR
Figure 7. Cyclo-DPAKKR reduces demyelination and axonal degeneration in a p75NTR-dependent manner. Histologic analyses of
longitudinal sciatic nerve sections of EAN mice following daily treatment of either cyclo-DPAKKR (10 mg/kg) or control peptide
(cyclo-ADPAKKR, 10 mg/kg) in p75NTR HET or WT littermate control mice from day 1. All tissues were collected at day 23 (disease
peak; data: mean SEM, 95% confidence interval, ANOVA with Tukey’s post hoc testing n  3 mice/genotype/group,
p  0.05, p  0.01, p  0.001). A, B, Representative SCoRe images (A) and quantification (B) of SCoRe signal as a percentage
of total area measured. WT mice treated with cyclo-DPAKKR display a greater percentage area of SCoRe reflected signal than control
peptide, indicating more myelinated axons. Cyclo-DPAKKR exerts no significant influence on HET mice compared with control peptide
(scale bar, 200 m). C, D, Representative images (C) of Caspr immunostaining and quantification (D) of node distance between
adjacent Caspr paranodes. WT mice treated with cyclo-DPAKKR demonstrate significantly shorter mean node distance compared
with mice treated with control peptide. Cyclo-DPAKKR exerts no significant influence on HET mice compared with control peptide
(scale bar, 1 m, minimum 70 nodes per mouse). E, F, Representative images (E) of APP and III-tubulin double immunostaining and
quantitation (F) of the percentage of APP axonal area colocalizing with II-tubulin. Cyclo-DPAKKR treatment significantly reduced
the percentage of APP colocalization with II-tubulin compared with the control peptide in WT, but not in HET mice (scale bar,
5 m; scale in inset, 20 m).
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induced signaling is neurotrophic. In this study, we found
that cyclo-DPAKKR administration significantly protected
against EAN-induced axonal damage, suggesting a neu-
roprotective effect. These findings collectively suggest
that cyclo-DPAKKR administration in the context of de-
myelinating neuropathies may not only limit demyelination
but also potentially directly ameliorate secondary axonal
degeneration and neuronal loss. Further, we have previ-
ously identified that cyclo-DPAKKR selectively targets
neuronally expressed p75NTR to promote peripheral nerve
myelination (Xiao et al., 2013). Thus, it is plausible that
cyclo-DPAKKR could directly target neurons to promote
both their survival and remyelination, thus effectively ame-
liorating EAN-induced neuropathology, which ultimately
determines disease progression and severity.
Interestingly, macrophages and T cells also express
p75NTR (Flügel et al., 2001; Pérez-Piñera et al., 2006). In
adition, our data also show that cyclo-DPAKKR reduced
immune cell infiltration into affected peripheral nerves,
suggesting cyclo-DPAKKR may act by more than one
mechanism to ameliorate disease severity in EAN. How-
ever, based on clinical scoring, cyclo-DPAKKR-treated
EAN animals still become sick, indicating that cyclo-
DPAKKR itself does not block antigen presentation or the
induction of T-cells. We have shown that neither injection
of p75NTR antisense oligonucleotides nor the genetic
knockout of p75NTR impedes the induction of experimen-
tal autoimmune encephalomyelitis (Soilu-Hanninen et al.,
1999), a T-cell-mediated autoimmune disease in the CNS
that has similar pathogenesis to EAN in the PNS. Collec-
tively, this suggests that macrophage expression of
p75NTR may not play a significant role in EAN induction,
but it nevertheless remains unclear whether the observed
decrease in infiltrating macrophages is a direct effect on
the macrophages themselves, or is an indirect effect sec-
ondary to myelin repair.
While the utility of p75NTR heterozygous mice, in which
there is a global p75NTR haploinsufficiency, enabled iden-
tification of the requirement of p75NTR for cyclo-DPAKKR
to exert its therapeutic benefit, it does not enable direct
insight into the specific pathologic processes that cyclo-
DPAKKR influences. Whether this is reduced axonal
damage, enhanced myelin repair or immunomodulation
remains unclear. This technical limitation precludes iden-
tification of a clear-cut cellular mechanism underlying the
beneficial effects that cyclo-DPAKKR exerts on EAN.
Thus, future studies are required to determine the precise
mechanisms of cyclo-DPAKKR action through adopting
inducible genetic approaches in which p75NTR is selec-
tively deleted from peripheral neurons, Schwann cells or
immune cells in the adult PNS, without interfering with the
normal development of these cells. Future experiments
are also required to determine the therapeutic efficacy of
cyclo-DPAKKR on EAN under different treatment para-
digms, such as commencing treatment after disease
symptoms appear.
In summary, we have identified that cyclo-DPAKKR, a
structural mimetic of the region of BDNF that binds to
p75NTR, ameliorates EAN disease severity and functional
deficits accompanied by strong neuroprotection against
myelin and axonal damage, effects dependent on p75NTR
expression. Interestingly, cyclo-DPAKKR itself displays
drug-like properties, in that it is of low molecular weight,
metabolically stable and readily crosses cell membranes
(Fletcher et al., 2008; Fletcher and Hughes, 2009). Demy-
elination followed by axonal damage is a common and
integral component of demyelinating diseases, and our
work identifying cyclo-DPAKKR exerts p75NTR-dependent
neuroprotective effects on EAN provides new insight into
the future development of neuroprotective therapeutics
for peripheral demyelinating diseases.
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